Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, Asia and the Middle East, Africa, and internationally. It operates through two segments: Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company produces single-ply roofing products, and warranted roof systems and accessories, including ethylene propylene diene monomer, thermoplastic polyolefin and polyvinyl chloride membrane, polyiso insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. It also offers building envelope solutions, including high-performance waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid and sheet applied air/vapor barriers, sealants/primers and flashing systems, roof coatings and mastics, spray polyurethane foam and coating systems, block-molded expanded polystyrene insulation, and engineered products for HVAC applications. It sells its products under the Carlisle SynTec, Versico, WeatherBond, Hunter Panels, Resitrix, and Hertalan brands. Carlisle Companies Incorporated was founded in 1917 and is headquartered in Scottsdale, Arizona.

Carlisle Companies Incorporated

Citi analyst Laura Sutcliffe maintained a Hold rating on CSL today and set a price target of A$160.00. According to TipRanks, Sutcliffe is a 3-star...

Citi Sticks to Their Hold Rating for CSL (CMXHF)

CSL ( ($AU:CSL) ) has provided an announcement. CSL Limited has confirmed updated arrangements for its previously announced on‑market share buy‑bac...

CSL Appoints J.P. Morgan as Broker for On‑Market Share Buy‑Back

CSL ( ($AU:CSL) ) has provided an announcement. CSL Limited is a global biotechnology company that develops and supplies vaccines, plasma-derived t...

CSL Seeks ASX Quotation for New Shares from Employee Incentive Plan

CSL ( ($AU:CSL) ) has issued an announcement. CSL Limited has disclosed a change in director Brian McNamee’s indirect interests, with securities he...

CSL Director Brian McNamee Increases Indirect Equity Exposure via Rights Plan

CSL ( ($AU:CSL) ) just unveiled an announcement. CSL Limited has notified the market of the issue of 12,809 unquoted rights securities, designated ...

CSL Issues New Unquoted Employee Rights Under Incentive Scheme

UBS analyst David Low maintained a Buy rating on CSL today and set a price target of A$181.00. Low covers the Healthcare sector, focusing on stocks...

UBS Sticks to Its Buy Rating for CSL (CMXHF)

CSL ( ($AU:CSL) ) has issued an announcement. CSL Limited has struck new agreements with the U.S. Administration that will see its medicines suppli...

CSL Aligns U.S. Drug Pricing and Boosts Plasma Manufacturing with $1.5bn Expansion

In a report released today, Steven Wheen from Jarden upgraded CSL to a Buy, with a price target of A$207.00. Wheen covers the Healthcare sector, fo...

Positive Report for CSL (CMXHF) from Jarden

The latest update is out from Recrusul SA ( ($BR:RCSL3) ). Recrusul S/A’s board has approved a proposal for a reverse split of all its common and p...

Recrusul Proposes Reverse Share Split to Support Liquidity and Compliance

Ord Minnett analyst maintained a Hold rating on CSL today and set a price target of A$152.50. In addition to Ord Minnett, CSL also received a Hold ...

Ord Minnett Sticks to Their Hold Rating for CSL (CMXHF)

In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on CSL, with a price target of A$172.00. Bailey covers the Hea...

Morgan Stanley Remains a Buy on CSL (CMXHF)

In a report released today, Thomas Wakim from Bell Potter maintained a Hold rating on CSL, with a price target of A$150.00. According to TipRanks, ...

Bell Potter Keeps Their Hold Rating on CSL (CMXHF)

Macquarie analyst maintained a Hold rating on CSL today and set a price target of A$108.00. In addition to Macquarie, CSL also received a Hold from...

Macquarie Sticks to Its Hold Rating for CSL (CMXHF)

In a report released today, David Low from UBS maintained a Buy rating on CSL, with a price target of A$158.00. According to TipRanks, Low is a 3-s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CSL	$334.01	+1.29%	234.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CSL	$334.01	+1.3%	234.93K
3
4
5
6

CSL

Get Carlisle Companies Incorporated Data in Excel

Get Carlisle Companies Incorporated Data in Excel